life science companies that transform the lives of patients worldwide
Improving patients lives
(Nasdaq: AUPH, TSX: AUP)
life science companies that transform the lives of patients worldwide
Acquired by UCB
life science companies that transform the lives of patients worldwide
Building Better Biologics
(NYSE: ZYME)
Acquired by Gilead Sciences
$11.2B
life science companies that transform the lives of patients worldwide
life science companies that transform the lives of patients worldwide
The immune system preserved
(Nasdaq: GTHX)
ICIZED.
Acquired by Stryker
$1.65B
life science companies that transform the lives of patients worldwide
Severe Asthma
FORMED.
Acquired by Cephalon
$550 million
life science companies that transform the lives of patients worldwide
Lumira Ventures partners with exceptional entrepreneurs to build life science companies that transform the lives of patients worldwide.
Trending
Iterion Therapeutics Secures $17 Million to Advance Development of Tegavivint in Multiple Tumor Settings
February 16, 2021
Series B financing to support ongoing Phase 1/2a clinical trial of Tegavivint in desmoid tumors and initiation of clinical trials in acute myeloid leukemia, non-small cell lung cancer and pediatric... Learn More
Lumira portfolio company Notch therapeutics closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies
February 10, 2021
VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ — Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer,... Learn More
Fonds de solidarité FTQ Invest US$17.7 Million in Lumira IV Life Sciences Fund
February 4, 2021
Montréal, February 4, 2021 – As part of its strategy to support Québec’s life sciences sector through well-performing specialized funds, the Fonds de solidarité FTQ (“Fonds”) is investing... Learn More
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
January 25, 2021
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved... Learn More
Team Lumira
Our investment team of 12 professionals has over 225 years of collective experience founding, managing and investing in healthcare and life sciences companies. We value collaboration, creativity and challenging conventional wisdom.
Philanthropy
Lumira donates a portion of partner time and profits to support the research, translational medicine and healthcare access missions of over a dozen leading healthcare foundations.
Contact Us
Our team is strategically situated across North America to identify innovative companies within and outside the traditional start-up hubs, and help them access capital, talent and strategic partners.
Toronto
141 Adelaide Street
Suite 770
Toronto, ON
Canada, M5H 3L5
416.213.4223
Montreal
Espace CDPQ
3, Place Ville Marie
Bureau 12350, Niveau L
Montreal, QC
Canada, H3B 0E7
514.844.6927
Vancouver
1021 West Hastings Street,
9th floor
Vancouver, BC
Canada, V6E 0C3
604.558.5156
Boston
303 Wyman Street
Suite 300
Waltham, MA,
USA, 02451-1208
781.530.3868